Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
World J Gastroenterol. 2013 Dec 21;19(47):8867-72. doi: 10.3748/wjg.v19.i47.8867.

Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy.

Author information

  • 1Il Han Song, Young Kwang Choo, Division of Hepatology, Department of Internal Medicine, Dankook University College of Medicine, Cheonan 330-715, South Korea.

Abstract

Hepatocellular carcinoma (HCC) is a grave primary liver cancer that has a limited therapeutic option because it is generally diagnosed later in an advanced stage due to its aggressive biologic behavior. The early detection of HCC has a great impact on the treatment efficacy and survival of patients at high risk for cancer. Potential host, environmental, and virus-related risk factors have been introduced. Hepatitis B virus (HBV) is a major cause of end-stage liver diseases such as liver cirrhosis or HCC in endemic areas, and its serologic or virologic status is considered an important risk factor. HCC risk prediction derived from the identification of major risk factors is necessary for providing adequate screening/surveillance strategies to high-risk individuals. Several risk prediction models for HBV-related HCC have been presented recently with simple, efficient, and readily available to use parameters applicable to average- or unknown-risk populations as well as high-risk individuals. Predictive scoring systems of risk estimation to assess HCC development can provide the way to an evidence-based clinical approach for cost- and effort-effective outcomes, capable of inducing a personalized surveillance program according to risk stratification. In this review, the concepts and perspectives of the risk prediction of HCC are discussed through the analysis of several risk prediction models of HBV-related HCC.

KEYWORDS:

Chronic hepatitis B; Hepatitis B virus; Hepatocellular carcinoma; Risk factors; Risk prediction

PMID:
24379609
[PubMed - indexed for MEDLINE]
PMCID:
PMC3870537
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk